$DRIO
DarioHealth Corp.

2017 Q1 Form 10-Q Financial Statement

#000114420418028285 Filed on May 15, 2018

View on sec.gov

Income Statement

Concept 2017 Q1
Revenue $1.007M
YoY Change 77.29%
Cost Of Revenue $901.0K
YoY Change 34.48%
Gross Profit $106.0K
YoY Change -203.92%
Gross Profit Margin 10.53%
Selling, General & Admin $3.840M
YoY Change 170.42%
% of Gross Profit 3622.64%
Research & Development $470.0K
YoY Change 18.39%
% of Gross Profit 443.4%
Depreciation & Amortization $43.00K
YoY Change -57.84%
% of Gross Profit 40.57%
Operating Expenses $4.311M
YoY Change 136.74%
Operating Profit -$4.205M
YoY Change 118.67%
Interest Expense -$1.210M
YoY Change 175.0%
% of Operating Profit
Other Income/Expense, Net -$1.208M
YoY Change -264.58%
Pretax Income -$5.410M
YoY Change 129.24%
Income Tax
% Of Pretax Income
Net Earnings -$5.413M
YoY Change 355.26%
Net Earnings / Revenue -537.54%
Basic Earnings Per Share
Diluted Earnings Per Share -$15.03M
COMMON SHARES
Basic Shares Outstanding 7.977M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.100M
YoY Change -62.65%
Cash & Equivalents $2.817M
Short-Term Investments $200.0K
Other Short-Term Assets
YoY Change
Inventory $800.0K
Prepaid Expenses
Receivables $500.0K
Other Receivables $700.0K
Total Short-Term Assets $5.100M
YoY Change -50.0%
LONG-TERM ASSETS
Property, Plant & Equipment $900.0K
YoY Change 28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $900.0K
YoY Change 12.5%
TOTAL ASSETS
Total Short-Term Assets $5.100M
Total Long-Term Assets $900.0K
Total Assets $6.000M
YoY Change -45.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.500M
YoY Change 150.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.700M
YoY Change 81.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.700M
Total Long-Term Liabilities $0.00
Total Liabilities $2.800M
YoY Change -17.65%
SHAREHOLDERS EQUITY
Retained Earnings -$51.72M
YoY Change 14.93%
Common Stock $6.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.233M
YoY Change
Total Liabilities & Shareholders Equity $5.985M
YoY Change -45.41%

Cashflow Statement

Concept 2017 Q1
OPERATING ACTIVITIES
Net Income -$5.413M
YoY Change 355.26%
Depreciation, Depletion And Amortization $43.00K
YoY Change -57.84%
Cash From Operating Activities -$3.083M
YoY Change 46.11%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$10.00K
YoY Change -200.0%
Cash From Investing Activities -$9.000K
YoY Change -70.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $4.816M
YoY Change -37.7%
NET CHANGE
Cash From Operating Activities -$3.083M
Cash From Investing Activities -$9.000K
Cash From Financing Activities $4.816M
Net Change In Cash $1.724M
YoY Change -69.16%
FREE CASH FLOW
Cash From Operating Activities -$3.083M
Capital Expenditures $0.00
Free Cash Flow -$3.083M
YoY Change 43.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-45000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1208000 USD
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-44000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5413000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2919000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5413000 USD
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2919000 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7195801 shares
CY2018Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
230000 USD
CY2017Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1585000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2766000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3083000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
55000 USD
CY2017Q1 drio Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
4816000 USD
CY2018Q1 drio Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
6034000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4816000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6034000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1724000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3323000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1093000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2817000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000 USD
CY2017Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
262000 USD
CY2018Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
219000 USD
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1195000 USD
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1000 USD
CY2018Q1 us-gaap Depreciation
Depreciation
53000 USD
CY2017Q1 us-gaap Depreciation
Depreciation
43000 USD
CY2018Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
3000 USD
CY2017Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
9000 USD
CY2017Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
323000 USD
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
861000 USD
CY2018Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
717000 USD
CY2018Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
195000 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
230000 USD
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1585000 USD
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1000 USD
CY2018Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1000 USD
CY2017Q1 drio Bank Charges
BankCharges
5000 USD
CY2018Q1 drio Bank Charges
BankCharges
42000 USD
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8000 USD
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
161000 USD
CY2017 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
874000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60000 USD
CY2017 drio Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity
8655000 USD
CY2017 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
0 USD
CY2017 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
CY2018Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; WIDTH: 0.79in; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> <div>NOTE 3: -</div> </td> <td style="TEXT-ALIGN: left; TEXT-INDENT: 0in; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> <div>UNAUDITED INTERIM FINANCIAL STATEMENTS</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The accompanying unaudited interim consolidated financial statements as of March 31, 2018, have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company's consolidated financial position as of March 31, 2018, and the Company's consolidated results of operations and the Company's consolidated cash flows for the three months ended March 31, 2018. Results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
906000 USD
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P10M28D
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16480164 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16480164 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14074238 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14074238 shares
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1234080 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1234080 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-6541000 USD
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1294000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
139000 USD
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9470000 USD
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2865000 USD
CY2017 drio Preferred Stock Issued During Period Value New Issue
PreferredStockIssuedDuringPeriodValueNewIssue
3711000 USD
CY2018Q1 drio Preferred Stock Issued During Period Value New Issue
PreferredStockIssuedDuringPeriodValueNewIssue
3124000 USD
CY2017 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1514000 USD
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
707000 USD
CY2017 drio Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
0 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
CY2018Q1 drio Increase Decrease In Other Receivables And Prepaid Expense
IncreaseDecreaseInOtherReceivablesAndPrepaidExpense
-38000 USD
CY2017Q1 drio Increase Decrease In Other Receivables And Prepaid Expense
IncreaseDecreaseInOtherReceivablesAndPrepaidExpense
210000 USD
CY2018Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-82000 USD
CY2017Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
256000 USD
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
70000 USD
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
0 USD
CY2018Q1 drio Payment For Directors And Consultants Under Shares For Salary Program
PaymentForDirectorsAndConsultantsUnderSharesForSalaryProgram
85000 USD
CY2017Q1 drio Payment For Directors And Consultants Under Shares For Salary Program
PaymentForDirectorsAndConsultantsUnderSharesForSalaryProgram
183000 USD
CY2018Q1 drio Reclassifiacation Of Warrants From Liability To Equity
ReclassifiacationOfWarrantsFromLiabilityToEquity
0 USD
CY2017Q1 drio Reclassifiacation Of Warrants From Liability To Equity
ReclassifiacationOfWarrantsFromLiabilityToEquity
8655000 USD
CY2018Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
161000 USD
CY2018Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6034000 USD
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-272000 USD
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-39000 USD
CY2018Q1 us-gaap Inventory Write Down
InventoryWriteDown
6000 USD
CY2017 us-gaap Inventory Write Down
InventoryWriteDown
190000 USD
CY2018Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
USD

Files In Submission

Name View Source Status
0001144204-18-028285-index-headers.html Edgar Link pending
0001144204-18-028285-index.html Edgar Link pending
0001144204-18-028285.txt Edgar Link pending
0001144204-18-028285-xbrl.zip Edgar Link pending
drio-20180331.xml Edgar Link completed
drio-20180331.xsd Edgar Link pending
drio-20180331_cal.xml Edgar Link unprocessable
drio-20180331_def.xml Edgar Link unprocessable
drio-20180331_lab.xml Edgar Link unprocessable
drio-20180331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv493035_10q.htm Edgar Link pending
tv493035_ex31-1.htm Edgar Link pending
tv493035_ex31-2.htm Edgar Link pending
tv493035_ex32-1.htm Edgar Link pending
tv493035_ex32-2.htm Edgar Link pending